RVMD - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.